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Airways chronic inflammatory conditions in asthma and COPD are characterized by tissue remodeling, being smooth
muscle hyperplasia, the most important feature. Non-neuronal and neuronal Acetylcholine acting on muscarinic
receptors (MAChRs) has been postulated as determinant of tissue remodeling in asthma and COPD by promoting
proliferation and phenotypic changes of airway smooth muscle cells (ASMC). The objective was to evaluate proliferative
responses to muscarinic agonist as carbamylcholine (Cch) and to identify the MAchR subtype involved. ASMC were
isolated from tracheal fragments of Sprague–Dawley rats by enzymatic digestion. Proliferation assays were performed
by MTS-PMS method. Viability was confirmed by trypan blue exclusion method. Mitogens as, epidermal growth factor
(EGF), Tumor necrosis factor-alpha (TNF-α) and fetal bovine serum (FBS) increased ASMC proliferation (p < 0.05, n = 5).
Cch alone increased ASMC proliferation at 24 and 48 hrs. However, combination of Cch with other mitogens exhibited
a dual effect, synergistic proliferation effect in the presence of EGF (5 ng/mL) and 5% FBS and inhibiting the
proliferation induced by 10% FBS, EGF (10 ng/mL) and TNF-α (10 ng/mL). To determine the MAChR subtype
involved in these biological responses, a titration curve of selective muscarinic antagonists were performed. The
Cch stimulatory and inhibitory effects on ASCM proliferation was blocked by AF-DX-116 (M2AChR selective antagonist),
in greater proportion than 4-DAMP (M3AChR selective antagonist), suggesting that the modulation of muscarinic
agonist-induced proliferation is M2AChR mediated responses. Thus, M2AChR can activate multiple signal transduction
systems and mediate both effects on ASMC proliferation depending on the plethora and variable airway
microenvironments existing in asthma and COPD.
Keywords: Airway smooth muscle, Muscarinic receptors, Carbamylcholine, ASMC inhibitionBackground
Chronic inflammatory conditions of the airways are usu-
ally associated with the development of structural changes
of the airways; a phenomenon commonly described as air-
way remodeling. This process is seen in both asthma and
Chronic Obstructive Pulmonary Disease (COPD), albeit
the nature, localization and extent of the remodeling are
variable [1-4]. Airway remodeling is progressive and the
degree of structural changes correlates with disease sever-
ity [4]. In this sense, the Airway Smooth Muscle Cells
(ASMC) hyperplasia has been postulated as the main
mechanism of airway smooth muscle thickening [5,6].
ASMC are multifunctional cells that have high pheno-
typic plasticity. These cells can shift between different* Correspondence: hmag5@hotmail.com
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distribution, and reproduction in any mediumphenotypes depending on the stimulation conditions.
Accordingly, mitogenic factors can induce the reversible
transition to “synthetic-proliferative” phenotype, character-
ized by high capacity for cell proliferation and secretion [7].
Several mediators, such as growth factors, cytokines, extra-
cellular matrix components, and G protein-coupled recep-
tors (GPCR) agonists have been found in bronchoalveolar
lavage fluid of asthmatics. Among the mediators identified
include epidermal growth factor (EGF) and tumor necrosis
factor-alpha (TNF-α) [8] and acetylcholine [9].
EGF binds to receptors with intrinsic tyrosine kinase
activity [10]. All EGF receptor (EGFR) subtypes are ex-
press by ASMC. However, that exerts its effect by acting
on the family 1 and 2 [10,11]. Furthermore, this growth
factor has been shown as the most potent for ASMC
proliferation stimulation. EGFR activation in ASMC trig-
gers mitogenic pathways through p21Ras and PI3-K,entral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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dues of several transcription factors by mitogen-activated
protein kinases (MAP kinases). Thus, DNA synthesis is
promoted and initiates the cell cycle [10,12].
The biological effects of TNF-α are mediated through
two receptors of similar affinity (TNF-R1, CD120a; 55-kd
and TNF-R2, CD120b, 75-kD) [13]. In experimental
models have been demonstrated their contribution to
chronic inflammation and airway hyperresponsiveness
mediated by TNF-R1 [14-16]. ASMC express both TNF-R
subtypes [15], whose stimulation induces an increase of
proliferation either directly or through other mediators
[17]. In this sense, TNF-α can induce MAPK pathway
activation including ERKs, p38 MAPK and JNK [12,15,16].
Acetylcholine (Ach) is agonist of muscarinic receptors
(MAchRs) that traditionally associated with airway smooth
muscle contraction and mucus secretion. Recently it has
been postulated as determinant of bronchial remodeling
[18]. There are two sources of Ach in the airways: 1)
neural, provided by parasympathetic fibers, from vagal
nerve and 2) non-neural, from airway epithelium and in-
flammatory cells present in the chronic inflammation
process, currently found in asthma [19]. ASMC express
two sub-types of MAChRs: Muscarinic receptor type 2
(M2AChR) and muscarinic receptor type 3 (M3AChR),
whose activation promote synthetic functions, prolifera-
tion and phenotypic changes depending on stimulation
conditions [19-21]. ASMC proliferation induced by ACh
is reversed by the muscarinic antagonists, such as tiotro-
pium bromide [22]. ACh and others agonists of GPCR are
not able by themselves to stimulate ASMC proliferation,
but enhance the action of growth factors by different
signal pathways [23]. However, the results differ between
different animal models. Thus, the aim was to study in rat
ASMC, the proliferative responses to a muscarinic
agonist such as carbamylcholine (Cch), and to establish
the MAChR subtype involved. In addition, to evaluate
as Control, the classic mytogenic responses induced by
fetal bovine serum (FBS), EGF and TNF-α. A prelimin-
ary description of this work has been reported [24].
Methods
ASMC were obtained from tracheas of female Sprague–
Dawley rats (12–14 weeks, weighing between 300–350 g)
from animal facility of the Instituto de Medicina Experi-
mental (I.M.E) of the Universidad Central de Venezuela
(U.C.V). The animals were maintained according to inter-
national standards for animal care and experimental proto-
col was approved by the Bioethics Committee of I.M.E.
Isolation and culture of rat airway smooth muscle cells
Primary cultures of rat ASMC were established as previ-
ously reported [25-27]. Rat trachea was dissected in
ice-cold phosphate- buffer saline (PBS) solution, pH 7.4(composition in g/dL: 0.2 KH2PO4, 0.8 NaCl, 1.15
Na2HPO4). The epithelium was removed, and muscle
were gently separated from underlying connective tissue
in small bundles, which were placed in digestion solution
(Ringer plus Ca2+) containing 4 mg/mL collagenase II
(Worthington®, UK) and 0.6U/mL dispase (Gibco®, USA)
by 50–60 min at 37°C under 5% CO2 Atmosphere. The
cell suspension was centrifuged at 500xg by 15 min. Cell
suspensions and explants were separately incubated in
25-cm2 flasks at 37°C in a humidified atmosphere of 5%
CO2 for 16–24 days (incubator NUAIRE™). The cells were
cultured in Dulbecco’s modified Eagle’s medium/F-12
(DMEM/F-12; Gibco®, USA) supplemented with 10% FBS
(Gibco®, USA), 1% L-Glutamine (Gibco®, USA), 2% penicil-
lin/streptomycin (Gibco®, USA), 2% amphotericin (Gibco®,
USA) and were passaged when confluent using trypsin/
EDTA (0.5 g/L porcine trypsin, 0.2 g/L EDTA, 4Na/L) of
Hanks’ balanced salt solution (HBSS); Sigma®, USA. Cells
between passages 3 and 7 were used for all experiments.
Proliferation assays
ASMC proliferation was estimated by the nonradioactive
method (MTS-PMS assay) based on the formation of tetra-
zolium salts [28] using, CellTiter 96® AQueous (Promega®,
USA). A fixed number of cells were seeded onto 96 wells
plates. After 24 hrs, culture medium was changed by
medium without FBS to equilibrate cell cycle in G0/G1
phase. After 12–24 hrs, cells were incubated at 37°C and
5% CO2 with solution containing the treatment according
each experimental conditions using the following com-
pounds: AF-DX-116 (Tocris®, USA), 4-DAMP (Tocris®,
USA), carbamylcholine chloride (Cch; Sigma®, USA), hu-
man recombinant EGF (Chemicon International®, USA),
rat recombinant TNF-α (Chemicon International®, USA)].
After, the exposure time finished, 100 μL of medium
plus 10 μL MTS [3-(4,5-dimethylthiazol-2yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]-PMS
[Phenazine Methosulfate]/well, and incubated for add-
itional 90 min. The cell proliferation were determinated
measuring optical density (OD) at λ = 492 nm, which is
proportional measure to the number of viable cells in
wells.
Trypan blue dye exclusion assay
Proliferation and viability was confirmed by trypan blue
0.1% exclusion method [29]. A fixed number of cells
were seeded onto 6 wells plates with 2 mL of medium
for 24 hrs. Then, culture medium was changed by non-
supplemented medium to equilibrate cell cycle in G0/G1
phase. After 12–24 hrs, cells were incubated at 37°C and
5% CO2 with solution containing each compound as ex-
perimental condition described. After 72 hrs, the cells
were detached using trypsin/EDTA and centrifuged at
500xg for 15 min. The cells were vigorously resuspended
Figure 1 Rat ASMC proliferation in response to FBS, EGF and
TNF-α. ASMC (1 × 103 cells/well) were cultured in 96 wells plates at
37°C/5%CO2 for 24, 48 and 72 hrs in a medium without FBS (basal; ●),
in presence of 5% FBS (Δ), 10% FBS (▼), EGF 10 ng/mL (□), TNF-α 10 ng/
mL (♦). Cell proliferation was determined using a colorimetric method
(MTS-PMS), measuring Optical Density (O.D.) at λ= 492 nm. Data is the
mean± ES of n= 5 experiments for triplicate. The proliferation responses of
each mitogen concentration vs. basal was significant (*) p < 0.05.
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a mixture of 10 μL of cell suspension plus 90 μL of 0.4%
trypan blue [dilution factor (DF) 1:10] by 5 min, then
20 μL of this mixture was placed in the hemocytometer
and observed under light microscopy. All cells in central
quadrant and four quadrants of corners were counted.
Cells number was estimated and the viability was deter-
mined (considering that only dead cells capture the dye)
using the equations previously described [30].
Statistical analysis
Values reported for all data are means ± SE. The statistical
significance of differences between means was determined
by an unpaired two-tailed Student’s t-test. Differences
were considered to be significant as p < 0.05. The parame-
ters log IC50 ± SE were estimated using the GRAPH PAD®
program.
Results and discussion
Rat ASMC proliferation in response to mitogens
Rat ASMC were incubated by 24, 48 and 72 hrs at
1 × 103cells/well in 96 well plates to evaluate its basal
proliferation and response to mitogens using MTS-PMS
method as shown in Figure 1. Basal proliferation of
ASMC was increased time-dependent manner being
significant at 24, 48 and 72 hrs. Mitogens increased
ASMC proliferation at all times of culture tested. The
mitogenic effectiveness at 72 hrs was the following: 10%
FBS > 5%FBS = EGF (10 ng/mL) = TNF-α 10 ng/mL (n = 5,
p < 0.05). In addition, EGF and TNF-α, showed a dual
effect increasing ASMC proliferation reaching maximum
effect at 10 ng/mL and higher concentration the prolifera-
tion effect decreased (data not shown).
Viability and cell proliferation were also evaluated by
trypan blue dye exclusion method as shown in Figure 2.
In these assays, ASMC were culture in 6 well plates at
2x105cells/well and mitogens as FBS, EGF, TNF-α, which
stimulated ASMC proliferation. However, there was not a
clear cut correlation between cell viability with cell prolif-
eration. In this sense, TNF-α (10 ng/mL) increased cell
proliferation but decreased cell viability (n = 5, p < 0.05),
indicating that TNF-α induces cell division and also pro-
motes cell death (apoptosis). The mechanism of cell death
induced by TNF-α could not be assessed with the method-
ology here applied.
ASMC proliferation has been studied for in several con-
ditions using various experimental animal and human
models. Fetal Bovine Serum (FBS) is a potent mitogenic,
that effect has been explained by the Reactive oxygen spe-
cies (ROS) generation [31]. Thus, exposing normal ASMC
to FBS induced proliferation, which can trigger signal
transduction leading to gene expression [32,33]. H2O2
treatment of airways myocytes successively stimulates the
MAP kinase superfamily members, which are importantin transduction of mitogenic signals to the nucleus [34].
This has important implications for the pathogenesis of
remodeling in the asthmatic airways, where myocytes are
Figure 2 Rat ASMC proliferation (A) and viability (B) in presence of mitogens and Cch. ASMC (2 × 105 cells/well) were cultured in 6 wells
plates at 37°C/5%CO2 for 48 hrs in presence of DMEM/F-12 medium (basal), 10% FBS, EGF 10 ng/mL, TNF-α 10 ng/mL and Cch 10-5,-3 M. Cell
proliferation and viability were determined using Trypan blue dye exclusion method. Data is the mean ± ES of n = 5 experiments for triplicate.
The proliferation responses of each mitogen concentration vs. basal was significant (*) p < 0.05.
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and macrophages that are present during the acute and
chronic inflammation process presents in asthma and
COPD. In addition, even serum can leaks from vascular
capillary system as a consequence of submucosal edema
and increased submucosal vascular permeability in asthma
[35]. In our experiments, FBS was the best mitogen for rat
ASMC, which confirmed the biological actions previously
reported.
Another mitogen studied was Tumor necrosis factor
(TNF-α), which is a potent proinflammatory cytokine
and its role as a potential mediator in asthma has been
well described [36,37]. Moreover, TNF-α has been re-
ported to be a poor mitogen and it can also modulate
cultured ASM cells to proliferate [38,39]. In our study,
these reported biologic actions of TNF-α on rat ASMC
were confirmed.
EGF is a mitogen that been reported to stimulate
ASMC growth in vitro [40] and this growth factor has
been shown to be upregulated in asthmatic human
airways [41]. In our work, we found that EGF was able
to stimulate rat ASMC proliferation and confirmed the
reported findings. In summary, both TNF-α and EGF
displayed similar mitogenic activity in rat ASMC. In
addition, both mitogens exhibited a dual effect on
ASMC proliferation.Muscarinic agonist (Cch) modulates rat ASMC
proliferation
The effects of muscarinic antagonists AF-DX-116 and
4-DAMP on this Cch modulation
Rat ASMC were incubated by 24, 48 and 72 hrs at
1x103cells/well in 96 well plates with increasing doses of
Cch in the presence and absence of 10% FBS (Figure 3).
Basal proliferation increased, in a dose dependent manner
by Cch, being significant at 24 and 48 hrs (n = 6, p < 0.05)
(Figure 3). However, Cch, decreases the ASMC prolife-
ration induced by 10% FBS (Figure 3). Thus, a dose-
dependent inhibitory effect on ASMC proliferation by Cch
was significant at 48 and 72 hrs. Proliferation inhibition
was not due to death cell because ASMC viability in pres-
ence of Cch was confirmed with blue dye exclusion
method (Figure 2).
To further evaluate the modulation properties of Cch
on ASCM proliferation, it was found that, at 24 hrs, Cch
stimulated cell proliferation and synergistically potentiated
the mitogenic effect of 5% FBS and a similar trend was ob-
served with EGF 5 ng/mL (n = 6, p < 0.05) (Figure 4).
Nonetheless, the Cch inhibitory effect was observed with
EGF 10 ng/mL and TNF-α 10 ng/ml being significant
(n = 6, p < 0.05) (Figure 4).
To determine the MAchR subtype involved in these
opposite effects displayed by Cch. ASMC at 1x103cells/
Figure 3 Rat ASMC proliferation response to muscarinic
agonist Cch. ASMC (1 × 103 cells/well) were cultured in 96 wells
plates at 37°C/5% CO2 with increasing concentration of muscarinic
agonist Cch in medium without FBS during 24 (○), 48 (□), y 72 (Δ),
and 10% FBS, during 24 (●), 48 (■), y 72 (▲) hrs. Cell proliferation
was determined using a colorimetric method (MTS-PMS), measuring
O.D at λ = 492 nm. Data are the mean ± SE of n = 6 experiments for
triplicate. Mitogen responses of 10% FBS vs. basal was significant
(*) p < 0.05. The inhibitory effect of Cch was significant (┼) p < 0.05.
Figure 4 Rat ASMC proliferation in response to Cch and
mitogens. ASMC (1 × 103 cells/well) were cultured in 96 wells plates
at 37°C/5% CO2 with DMEM/F-12 medium (basal), Cch 10
-3 M, 5%
FBS, EGF 5 and 10 ng/mL, and TNF-α 10 ng/mL during 24 hrs. Cell
proliferation was determined using a colorimetric method (MTS-PMS),
measuring O.D at λ = 492 nm. Data is the mean ± ES of n = 6
experiments for triplicate. Each mitogen proliferation responses vs
basal was significant (*) p < 0.05. Moreover, significant differences
(**) p < 0.05 between mitogen vs mitogen plus Cch condition
were found.
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5% FBS and 5% FBS plus Cch leading to a rise in cell
proliferation as exhibited in Figure 5. Under these
experimental conditions, ASMC were exposed to in-
creasing concentrations of preferential muscarinic an-
tagonist 4-DAMP (for M3AChR) and AF-DX-116-DS
(for M2AChR) as shown in Figure 5A. These muscarinic
antagonists reversed both, the 5% FBS induced prolifera-
tion activity and the Cch-induced proliferation (n = 4,
p < 0.05) as shown in Figure 5A. Unexpectedly, the 5%
FBS induced proliferation was inhibited by these muscar-
inic antagonists displaying, the log IC50 for 4-DAMP and
AFDX-116, which were similar as 4-DAMP+ FBS = −7.34
± 0.21 AFDX-116 + FBS = −7.26 ± 0.51. These results may
be explained by some inverse agonist actions described by
these muscarinic drugs [42]. This experimental findings
may be a research subject in the future.
Interestingly, in the case of the synergistic Cch and
FBS proliferation effect, both muscarinic antagonistswere able to inhibit such proliferation activity displaying
different values of the log IC50 for the 4-DAMP + FBS +
Cch = −7.38 ± 0.42 and AFDX-116 + FBS + Cch = −8.99 ±
0.45. From these data, there is two order of magnitude
of difference between these values supporting a pharma-
cological profile that AFDX 116 > 4-DAMP, that belongs
to an M2AchR.
Trying to understand this novel finding on the ability
of Cch to exhibit anti-proliferative properties especially
at high mitogen concentration (10% FBS). It was found,
this anti-mitogenic Cch effect was reversed, in a dose-
dependent manner, by preferential muscarinic antago-
nists as AF-DX-116 (M2AChR antagonist), which was
more efficient than 4-DAMP (M3AChR antagonist) to
reverse this novel Cch inhibition activity as shown in
Figure 5B. The proliferative stimulatory responses dis-
played by muscarinic antagonists reversed significantly
the anti-mitogenic Cch (1x10-5 M) action (p < 0.05).
Thus, the Log IC50 ± SE were 4-DAMP = −7.11 ± 0.71
and AFDX- = −9.40 ± 0.37 were estimated. The differ-
ence between these log IC50 values is more than 2 orders
of magnitude, that support a pharmacological profile is
AFDX 116 > > 4-DAMP clearly belongs to an M2AchR.
It important to point out that all Cch effects here
described on rat ASMC proliferation were affected by
Figure 5 Effect of selective muscarinic antagonists AF-DX-116 (M2AChR) and 4-DAMP (M3AChR) on ASMC proliferation at 5 and 10%
FBS. A. Effect of increasing concentration of AF-DX-116 and 4-DAMP on the synergistic effect induced by Cch in presence of 5% FBS. ASMC (1× 103
cells/well) were cultured in 96 wells plates for 72 hrs. Cell proliferation was determined using a colorimetric method (MTS-PMS), measuring O.D at
λ = 492 nm. (n = 5, for triplicate). The synergistic proliferation responses in the presence of 5% FBS and Cch (1 × 10-3 M) plus 5% FBS against basal
condition were significant different (┼) p < 0.05. The muscarinic antagonists inhibitory responses were significant against the “0” Cch condition
(*) p <0.05. The estimated Log IC50 ± SE were 4-DAMP+ FBS = −7.34 ± 0.21; 4-DAMP + FBS + Cch = −7.38 ± 0.42; AFDX-116 + FBS = −7.26 ± 0.51 and
AFDX-116 + FBS + Cch = −8.99 ± 0.45. B.- Effect of increasing concentrations of AF-DX-116 and 4-DAMP on the anti-proliferative effect induced by Cch
(1x10-5 M), in presence of 10% FBS. ASMC (1 × 103 cells/well) were cultured in 96 wells plates for 72 hrs. Cell proliferation was determined using a
colorimetric method (MTS-PMS), measuring O.D at λ = 492 nm. (n = 5, for triplicate). The muscarinic antagonists stimulatory proliferative
responses were significant (*) p < 0.05 against the anti-proliferative Cch (1x10-5 M). The estimated Log IC50 ± SE were 4-DAMP = −7.11 ± 0.71
and AFDX- = −9.40 ± 0.37.
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that these mitogenic and anti-mitogenic effects are
mediated, via muscarinic receptors, and nor through nic-
otinic receptors, which may be affected by Cch.
Interestingly, in our study model rat ASMC, muscarinic
agonist, Cch, displayed three distinct effects on ASMC
proliferation: 1) stimulatory effect by itself, 2) synergistic
effect, at low concentrations of mitogens (5% FBS, EGF
5 ng/mL), and 3) inhibitory effect, at maximum concentra-
tion of mitogens (10% FBS, 10 ng/mL of EGF or TNF-α)
as above described.
It is complex matter to explain these diverse biological
effects that are initiate by the binding of a neurotransmit-
ter (ACh) to muscarinic receptors (GPCR) at sarcolema
of ASMC, with the involvement of some intracellular
seconds messengers (cGMP, cAMP, Ca2+) that trigger sev-
eral intracellular signal cascades that cross-talk involving
protein-protein interactions and reversible posttrans-
lational modifications (phospho/dephosphorylation pro-
cesses) to activate or regulate the nuclear factors
involve in the DNA duplication and cell division, which
is a fast growing research field in the last 20 years.Neuronal and non-neuronal ACh, has been proposed to
promote airway remodeling and increased smooth muscle
thickening and airway hyperresponsiveness development
in asthma models, which was prevented by a specific an-
tagonist of M3AChR such as tiotropium bromide [19,43].
Classically, it has been claimed that agonist muscarinic
stimulation “in vitro” is not sufficient to induce ASMC
proliferation and only in combination with growth factors,
the mitogenic effect was observed [19,21,23]. In this sense,
we found a stimulatory effect on rat ASMC proliferation
by Cch, which was less potent than FBS, EGF and TNF-α.
Muscarinic stimulation has been associated with MAPK
and PI3-K activation [19-21]. Moreover, ERKs activation
and phosphorylation is reaching in response to agonist
of M2AChR and M3AChR. The M3AChR pathway is
linked to a Gq protein mediated and dependent of Raf-1
phosphorylation by PKC, whereas M2AChR pathway is
Gi/o protein mediated and depends on PI3-K activation
[43]. However, in human and bovine ASMC, MAChR
proliferative activation as well as others GPCRs requires
a growth factor to activate MAPK in sustained manner
[17,43]. Thus, gene transcription associated with cell
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G0 phase to G1 phase.
Muscarinic agonist synergistic effect on rat ASMC
proliferation in the presence of low doses of EGF and
5% FBS was observed. The co-administration of muscar-
inic agonists with EGF in human ASMC induces a syn-
ergistic proliferative stimulus. This effect was associated
with sustained activation of p70 S6 kinase [21,44], an ef-
fect mediated by Gq derived Gβγ subunits that activate
phosphatidylinositol-3-kinase (PI3K) in concert with the
EGF receptor [19,44]. In line with these findings, muscar-
inic receptor agonists induce an increase in proliferation
of airway smooth muscle cells in combination with
platelet-derived growth factor (PDGF), which is mediated
by Gq-protein-coupled M3AChR and appears to involve
a synergistic inhibitory phosphorylation of glycogen syn-
thase kinase-3 (GSK-3) [45].
Similar synergistic effects of muscarinic agonists in human
and bovine ASMC are antagonized by 4-DAMP and DAU
5884, in consequence appears to be M3AChR mediated [19].
However, our data obtained from rat ASMC incubated
with preferential muscarinic antagonists AF-DX-116
(for M2AChR) [46] and 4-DAMP (for M3AChR) suggest
that synergistic effect is mediated through the activation
of M2AChR (log IC50 AF-DX-116 < IC50 4-DAMP). Our
results suggest that constitutive activity of M2AChR
could be necessary to maintain ASMC proliferation in
5% FBS response. Additionally, M2AChR is coupled to a
pertussis toxin (PTX) sensitive Gi/o protein. Consequently,
in several studies have been reported that mitogenic effect
of Cch on human ASMC is antagonized by PTX [47,48].
To explain these synergists effects, a PTX sensitive signal
cascade involving p21Ras and MAPK activation induced
by muscarinic agonists may be consider [49] as reported,
in vascular smooth muscle cells, where PTX treatment de-
creased basal proliferation and response to FBS and PDGF
[50]. Interestingly, growth factors induce activation and
dissociation of heterotrimeric G proteins in many cell
types, either through direct (EGF→Gi/o, Gs, PDGF→
Gi/o) or indirectly interaction (PDGF/EDG1→Gi/o) [51].
Src and PI3-K activation by PDGF in bovine ASMC is me-
diated by a PTX-sensitive G protein [52]. Therefore, it is
possible that M2AChR/Gi/o protein/p21Ras and MAPK
signal cascade in response to Cch might be more efficient
to potentiate the signal transduction of growth factors
present in FBS. Nonetheless, synergistic effect of muscar-
inic agonists may involve a sustained activation of p70S6K
in promotion of protein synthesis related with cell cycle
transition [21,44] rather than increased of MAPK activa-
tion [44]. Moreover, glycogen synthase kinase-3β (GSK-3β)
could be another possible mediator due to it has been in-
volved in methacholine (muscarinic agonist) synergism on
human ASMC proliferation. Thus, an active form of GSK-
3β (dephosphorylated) inhibits cell proliferation throughnegative regulation of some mitogenic promoters such as
cyclin D1 accumulation in cell nucleus [45].
Briefly, muscarinic agonist synergism with other mito-
gens on rat ASMC proliferation could be mediated by
interactions between several pathways and signal trans-
duction effectors as GSK-3β, p70S6K and ERKs. During
the preparation of this manuscript, it was reported that
muscarinic agonists (metacholine) exhibits synergistic
effects on TGF-β1-induced proliferation, which were
reduced by tiotropium and the M2AChR subtype an-
tagonist gallamine, but not the M3AChR antagonist
DAU5884. Moreover, pertussis toxin treatment also pre-
vented the potentiation of TGF-β1-induced proliferation by
methacholine, via an M2AChR coupled to Gi/o protein.
These authors concluded that exposure to TGF-β1 induces
ASMC proliferation, which is enhanced by M2AChR stimu-
lation [53]. These explanations on the role of M2AChR are
similar to the ones here described for rat ASMC.
Muscarinic agonist inhibition of rat ASMC proliferation
is an original experimental finding of this work. This effect
was observed when ASMC were incubated with Cch plus
mitogens at its maximum doses for proliferation responses
such as 10% FBS. This inhibitory novel response seems to
be also mediated by M2AChR from pharmacological pro-
file responses (log IC50 AF-DX-116 < log IC50 4-DAMP).
Muscarinic agonist inhibition mechanism may be the
result of the activation of two signaling pathways: 1)
The cGMP/PKG activation cascade [54-58], and 2)
MAPK activation: p38 MAPK and JNK cascade [11]. In-
creased cGMP production by muscarinic agonist (Cch)
has been reported previously in bovine tracheal smooth
muscle [54-56]. Transduction mechanisms proposed
include MAchR stimulation, G protein activation and
subsequent activation of NO-sensitive-soluble guanylyl
cyclase (NO-sGC) and/or membrane-spanning Natri-
uretic Peptide Receptor guanylyl cyclase (NPR-GC).
Recently, we have described a M2AChR coupled to a Gi/o
protein-dependent process, that augmented NO-sGC
activity in bovine smooth muscle, independently of ni-
tric oxide (NO) [54,56]. Likewise, M3AChR/Gq protein
complexes have been associated with the NPR-GC-B
activation [54,56] producing cGMP, which can activate
PKG. This last nucleotide-dependent kinase can phos-
phorylate transcription factors associated with inhib-
ition of gene expression that promote cell cycle, also
induce increment of proteins that leads cell cycle arrest
as p21Cip1/Waf1 [58].
The involvement of these two GCs (sGC and/or NPR-
GC-B) in rat ASMC in response to Cch is supported by
some additional experimental evidences (data not shown):
1) Cch induced proliferation is blocked by sodium nitro-
prusside (SNP; NO donor). 2), Cch blocked synergistic ef-
fect on ASMC proliferation induced by ODQ, a selective
inhibitor of NO-sGC, and 3) Cch potentiates the inhibitory
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NPR-GC-B) on ASMC proliferation. All these add-
itional data suggest that inhibitory effect of Cch on
mitogen-induced ASMC proliferation could include the
activation of ones of these cGMP-dependent signaling
pathways above mentioned. The identification of the
members of the cGMP-PKG cascades related to this
M2AChR-dependent inhibitory effect on ASMC prolif-
eration is under intense investigation in our laboratory.
The fact that ASMC proliferation inhibition by Cch
was observed at high doses of mitogens leads to ask
whether inhibition is due to certain level of mitogenic
pathways activation, which are associated in parallel with
anti-proliferative pathway facilitation (e.g. ↑[cGMP]int)
or mitogenic pathways over-activation (e.g. p38MAPK
or JNK) trigger cell death [11,59]. Inhibition of cell pro-
liferation by muscarinic agonists has been reported in
ovarian cells [46], NIH3T3 cells [60], and cancer cells
[61], in most cases M3AChR and p21
Cip1 Waf1 expression
was involved in cell cycle arrest. The dual effects of Cch
on proliferation have also been reported for others cell
systems [62].
ASMC phenotype present in these assays may be another
factor that can influence these results. ASMC express both
M2AChR and M3AChR, in a proportion that depends of
species and cell phenotype. In ASMC with contractile
phenotype predominates M3AChR expression (~80%) [37].
Prolonged serum deprivation induces M3AChR transcrip-
tion and expression in ASMC that express contractile pro-
teins and generate a basal lamina rich in laminina. Airway
remodeling models suggest that M3AChR mediated ACh
effects “in vivo” [17-20]. Chronic activation of M3AChR
may constitute an “in vivo” mechanism for ASMC
phenotype modulation, which is crucial event in tissue
remodeling rather proliferation stimulation [18,28]. By
other hand, ASMC with synthetic-proliferative phenotype
express mainly M2AChR [63], which seem to be our case.
Therefore, cell population used in this work was heteroge-
neous in similar manner to ASMC “in vivo” [7]. Thus, the
M2/M3AChR ratio is 4:1, which has been described in
intact airway smooth muscle cells [64,65].
The exact cellular mechanisms underlying MAChR-
modulated DNA synthesis and ASMC proliferation are
not fully understood. ASMC proliferation involves sev-
eral intracellular pathways leading to DNA replication
and cell division as above discussed. In relation to this
novel inhibitory effect of muscarinic agonists here de-
scribed may improve our understanding of the intracel-
lular mechanisms underlying the activation of mitogenic
and anti-mitogenic pathways and provide insights for
therapeutic drug development. Recent evidence suggests
that ACh acting through muscarinic receptors may play
an inhibitory role in the airway remodeling. The anti-
cholinergic drug tiotropium bromide, which selectivelyantagonizes the M3AChR subtype, could be beneficial in
attenuating airway remodeling in chronic asthma [66].
These authors reported that in murine (BALB/c mice)
models of chronic asthma, sensitized and challenged to
ovalbumin, the expression of the M3AChR was inhibited
and the M2AChR was elevated by the administration of
tiotropium bromide. Our results on the role of M2AChR
inhibiting the mitogen-induced proliferation may be
relevant, which may be similar environment to the ones
present in chronic asthma, which can explain these in-
teresting experimental results of tiotropium bromide on
M3/M2AChR expression [66].
Conclusions
Muscarinic agonist has three effects on “in vitro” rat
ASMC proliferation: 1) stimulation, 2) synergism, and 3)
inhibition. Interestingly, both biological actions seem to
be mediated by M2AChRs through activation of distinct-
ive and multiple signal transduction pathways, which
may depend on the cell phenotype and the type and
mitogen concentration used. These findings are import-
ant in ASMC proliferation induced by ACh “in vivo”
especially on cells with synthetic-proliferative phenotype.
If, mitogenic and anti-mitogenic effects are both medi-
ated by the same receptor, leads us to propose an ASMC
proliferation modulation by ACh, via M2AChRs. Our data
here reported support the rationale about the need for the
developing of new muscarinic antagonists-derivated from
tiotropium bromide or similar compound that preferen-
tially antagonize the putative M3AChR involves in the
mitogen-induced ASMC proliferation associated to the
airway remodeling presents in chronic asthma and COPD
and increase the level of expression of this novel action of
M2AChR acting as anti-proliferation receptor.
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